會議預吿‖歸創通橋(2190.HK)2023上半年業績交流會:國內神經和外周血管介入龍頭繼續向前邁進

歸創通橋(2190.HK)是國內知名的專注於外周和神經血管介入、植入領域醫療器械創新研發、生產製造及銷售服務的上市公司。經過十餘年發展,公司已建立豐富全面的產品管線佈局,研發了一系列具有自主知識產權,達到國內甚至國際領先水平的產品,成長為國內神經和外周血管介入醫療器械市場的領導者。
隨着老齡化程度加深,中國的神經介入市場規模正在快速增長,但國內神經介入市場被外資壟斷,國產滲透率嚴重不足。此外,目前外周血管疾病仍是藍海市場,未來有望快速增長,據弗若斯特沙利文預估,到2030中國外周動脈介入市場將達到122億元,CAGR為15.7%。公司是國內神經和外周血管介入龍頭,在國產化替代的大背景下,疊加集採政策帶來市場集中度提升,公司憑藉平台化產品研發優勢及商業化規模優勢,有望爭取到更多市場份額。
本期格隆匯極調研非常榮幸邀請到了歸創通橋管理層團隊,為大家分享歸創通橋的業績亮點、業務優勢與公司長期發展潛力。

活動時間:8月25日(週五)14:00-15:00
演講嘉賓:首席財務官 袁泉衞先生
投資者關係經理 陳玉佳女士
參會方式:識別下方海報二維碼,添加格隆匯機構客服報名獲取參會密碼

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.